WallStSmart

AstraZeneca PLC (AZN)vsCastle Biosciences Inc (CSTL)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 16442% more annual revenue ($62.38B vs $377.13M). AZN leads profitability with a 17.7% profit margin vs -6.1%. AZN earns a higher WallStSmart Score of 68/100 (B-).

AZN

Strong Buy

68

out of 100

Grade: B-

Growth: 6.7Profit: 8.5Value: 6.0Quality: 5.5
Piotroski: 6/9Altman Z: 1.48

CSTL

Avoid

34

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 6.7Quality: 8.5
Piotroski: 3/9Altman Z: 3.11
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+4.3%)

Margin of Safety

+4.3%

Fair Value

$197.94

Current Price

$184.45

$13.49 discount

UndervaluedFair: $197.94Overvalued
CSTLUndervalued (+59.1%)

Margin of Safety

+59.1%

Fair Value

$79.14

Current Price

$32.75

$46.39 discount

UndervaluedFair: $79.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN5 strengths · Avg: 8.6/10
Market CapQuality
$293.73B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
21.3%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
29.6%8/10

Strong operational efficiency at 29.6%

EPS GrowthGrowth
23.5%8/10

Earnings expanding 23.5% YoY

Free Cash FlowQuality
$3.99B8/10

Generating 4.0B in free cash flow

CSTL4 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.1110/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
23.9%8/10

Revenue surging 23.9% year-over-year

Areas to Watch

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
26.8x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

CSTL4 concerns · Avg: 2.5/10
Market CapQuality
$1.05B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-4.1%2/10

ROE of -4.1% — below average capital efficiency

EPS GrowthGrowth
-51.6%2/10

Earnings declined 51.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.

Bull Case : CSTL

The strongest argument for CSTL centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 23.9% demonstrates continued momentum.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Bear Case : CSTL

The primary concerns for CSTL are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

AZN profiles as a mature stock while CSTL is a growth play — different risk/reward profiles.

CSTL carries more volatility with a beta of 0.95 — expect wider price swings.

CSTL is growing revenue faster at 23.9% — sustainability is the question.

AZN generates stronger free cash flow (4.0B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (68/100 vs 34/100), backed by strong 17.7% margins. CSTL offers better value entry with a 59.1% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Castle Biosciences Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests, particularly within the skin cancer sector, exemplified by its flagship product, DecisionDx®-Melanoma. This innovative test offers essential insights for risk stratification, enabling oncologists to make informed treatment decisions in managing melanoma. With a strong focus on precision medicine, coupled with an extensive research and development strategy, Castle Biosciences is poised for growth as it seeks to expand its offerings and meet critical clinical demands. By addressing the complexities inherent in oncology, the company not only aims to improve patient outcomes but also to generate substantial value for its investors.

Visit Website →

Want to dig deeper into these stocks?